dinoprostone - CISMeF

Preferred Label : dinoprostone;

MeSH definition : The most common and most biologically active of the mammalian prostaglandins. It exhibits most biological activities characteristic of prostaglandins and has been used extensively as an oxytocic agent. The compound also displays a protective effect on the intestinal mucosa.;

MeSH synonym : alpha, prostaglandin e2; prostaglandin e2alpha; pge2 alpha; prostaglandin e2; pge2alpha; e2alpha, prostaglandin; pge2; e2, prostaglandin; alpha, pge2; prostaglandin e2 alpha; e2 alpha, prostaglandin;

MeSH hyponym : prostenon; prepidil gel; Gel, Prepidil;

MeSH CAS label : Prosta-5,13-dien-1-oic acid, 11,15-dihydroxy-9-oxo-, (5Z,11alpha,13E,15S)-;

MeSH Related Number : 363-24-6 (Dinoprostone);

Registry Number MeSH : 363-24-6;

MeSH annotation : do not confuse with DINOPROST; /biosyn /physiol permitted;

Wikipedia link : https://en.wikipedia.org/wiki/Prostaglandin E2;

Codes EINECS : 206-656-6;

Is substance : O;

UNII : K7Q1JQR04M;

InChIKey : XEYBRNLFEZDVAW-ARSRFYASSA-N;

Details

Origin ID

D015232;

UMLS CUI

C0012472;

ATC code(s)
- dinoprostone [ATC Code]
Allowable qualifiers
- administration and dosage [MeSH Qualifier]
- adverse effects [MeSH Qualifier]
- agonists [MeSH Qualifier]
- analogs and derivatives [MeSH Qualifier]
- analysis [MeSH Qualifier]
- antagonists and inhibitors [MeSH Qualifier]
- biosynthesis [MeSH Qualifier]
- blood [MeSH Qualifier]
- cerebrospinal fluid [MeSH Qualifier]
- chemical synthesis [MeSH Qualifier]
- chemistry [MeSH Qualifier]
- classification [MeSH Qualifier]
- contraindications [MeSH Qualifier]
- deficiency [MeSH Qualifier]
- economics [MeSH Qualifier]
- genetics [MeSH Qualifier]
- history [MeSH Qualifier]
- immunology [MeSH Qualifier]
- isolation and purification [MeSH Qualifier]
- metabolism [MeSH Qualifier]
- pharmacokinetics [MeSH Qualifier]
- pharmacology [MeSH Qualifier]
- physiology [MeSH Qualifier]
- poisoning [MeSH Qualifier]
- radiation effects [MeSH Qualifier]
- standards [MeSH Qualifier]
- supply and distribution [MeSH Qualifier]
- therapeutic use [MeSH Qualifier]
- toxicity [MeSH Qualifier]
- urine [MeSH Qualifier]
Automatic exact mappings (from CISMeF team)
- Prostaglandin E2 Measurement [NCIt concept]
CISMeF manual mappings
- dinoprostone [Substance BNPC]
Currated CISMeF NLP mapping
- Dinoprostone [ICD-11 Extension code]
- Dinoprostone [ICHI extension code]
- Dinoprostone [SMS substance]
- Dinoprostone [NCIt concept]
- Dinoprostone (substance) [SNOMED CT concept]
- Prostaglandin E2 [NCIt concept]
- Prostaglandin E2 [ICD-11 Extension code]
- Prostaglandin E2 [LOINC component]
- Prostaglandin E2 [ICHI extension code]
- prostaglandin pge2 [SNOMED Notion]
Indexing information
- 7-(N-4'-acetylphenylpiperazino)-8-cyano-4-chloropyrido(3',2'-4,5)thieno(3,2-d)-1,2,3-triazine [MeSH Supplementary Concept]
- 8-cyano-4-(4-methylpiperidino)-7-morpholinopyrido(3',2'-4,5)thieno(3,2-d)-1,2,3-triazine [MeSH Supplementary Concept]
Pharmacological action(s)
- oxytocics [MeSH Descriptor]
Record concept(s)
- dinoprostone [MeSH concept]
- prepidil gel [MeSH concept]
- prostenon [MeSH concept]
Related MeSH Supplementary Concept(s)
- 11,15-O-dimethylprostaglandin E2 [MeSH Supplementary Concept]
- 11-deoxy,16,16-dimethyl prostaglandin E(2) [MeSH Supplementary Concept]
- 11-deoxy-11,12-methanoprostaglandin E2 [MeSH Supplementary Concept]
- 11-deoxy-11alpha-(2-hydroxyethylthio)-prostaglandin E2 methyl ester [MeSH Supplementary Concept]
- 11-deoxy-15-keto-13,14-dihydro-11 beta,16-cycloprostaglandin E2 [MeSH Supplementary Concept]
- 11-deoxyprostaglandin E2-1-alcohol [MeSH Supplementary Concept]
- 12-isoprostaglandin F(2alpha) [MeSH Supplementary Concept]
- 13,14-didehydroprostaglandin E2 [MeSH Supplementary Concept]
- 13,14-dihydro-16-phenyl-omega-tetranorprostaglandin E2 [MeSH Supplementary Concept]
- 13,14-dihydroprostaglandin E2 [MeSH Supplementary Concept]
- 15-deoxy-16-hydroxy-16-vinylprostaglandin E2 [MeSH Supplementary Concept]
- 15-fluoro-15-deoxyprostaglandin E2 [MeSH Supplementary Concept]
- 15-hydroperoxyprostaglandin E2 [MeSH Supplementary Concept]
- 15-keto-13,14-dihydroprostaglandin E2 [MeSH Supplementary Concept]
- 15-keto-13,14-dihydroprostaglandin E2-thyroglobulin conjugate [MeSH Supplementary Concept]
- 15-ketoprostaglandin E2 [MeSH Supplementary Concept]
- 16-methyl prostaglandin E2 [MeSH Supplementary Concept]
- 16-methyl-13,14-didehydroprostaglandin E2 [MeSH Supplementary Concept]
- 16-methyl-16-methoxyprostaglandin E2 [MeSH Supplementary Concept]
- 16-methyl-20-methoxy-PGE2 [MeSH Supplementary Concept]
- 17,17-dimethylprostaglandin E2 [MeSH Supplementary Concept]
- 17-(4-azidophenyl)-18,19,20-trinorprostaglandin E2 [MeSH Supplementary Concept]
- 17-phenyltrinorprostaglandin E2 [MeSH Supplementary Concept]
- 18,18,20-trimethylprostaglandin E2 [MeSH Supplementary Concept]
- 18-hydroxyprostaglandin E2 [MeSH Supplementary Concept]
- 19,20-dehydroprostaglandin E2 [MeSH Supplementary Concept]
- 19-hydroxyprostaglandin E2 [MeSH Supplementary Concept]
- 1a,1b-dihomoprostaglandin E2 [MeSH Supplementary Concept]
- 20-hydroxyprostaglandin E2 [MeSH Supplementary Concept]
- 20-isopropylidene prostaglandin E2 [MeSH Supplementary Concept]
- 20-methyl-13,14-didehydroprostaglandin E2 [MeSH Supplementary Concept]
- 8,12-epi-prostaglandin E2 [MeSH Supplementary Concept]
- 8-isoprostaglandin E2 [MeSH Supplementary Concept]
- 9-deoxy-9-chloro-15-deoxy-16-hydroxy-17,17-trimethylene-19,20-didehydroprostaglandin E2 [MeSH Supplementary Concept]
- 9-enol-prostaglandin E2 methyl ester trimethylsilyl ether [MeSH Supplementary Concept]
- CAY 10580 [MeSH Supplementary Concept]
- FCE 20700 [MeSH Supplementary Concept]
- HOE 260 [MeSH Supplementary Concept]
- N-acetylprostaglandin E2 carboxamide [MeSH Supplementary Concept]
- ONO AE 248 [MeSH Supplementary Concept]
- prostaglandin D2 ethanolamide [MeSH Supplementary Concept]
- prostaglandin E2 azidophenacyl ester [MeSH Supplementary Concept]
- prostaglandin E2 ethanolamide [MeSH Supplementary Concept]
- prostaglandin E2 glyceryl ester [MeSH Supplementary Concept]
- prostaglandin E2 methyl ester [MeSH Supplementary Concept]
- prostaglandin E2 methyl oxime [MeSH Supplementary Concept]
- prostaglandin F2alpha ethanolamide [MeSH Supplementary Concept]
- prostamide H2 [MeSH Supplementary Concept]
- sulprostone [MeSH Supplementary Concept]
- trimoprostil [MeSH Supplementary Concept]
- viprostol [MeSH Supplementary Concept]
Semantic type(s)
- Hormone [UMLS semantic type]
- Organic Chemical [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- Dinoprostone [ICD-11 Extension code]
- Dinoprostone [NCIt concept]
- Dinoprostone (substance) [SNOMED CT concept]
- Product containing dinoprostone (medicinal product) [SNOMED CT concept]
- dinoprostone [ATC Code]
- dinoprostone [Substance BNPC]
- dinoprostone preparation [SNOMED Notion]
- prostaglandin pge2 [SNOMED Notion]
Validated automatic mappings to BTNT
- dinoprostone [ATC Code]

Keyword's position in hierarchy(ies) :

Main resources

You can consult :

recommendations
documents concerning education
documents for patients